Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Ovarian Cancer treatment details. Biologic therapy. University of Texas MD Anderson Cancer Center, Houston, TX, United States

Survival: 14.9 months
Toxicity Grade: 3
Treatments: Biologic therapy
Country: United States
City/State/Province: Houston, TX
Hospital: University of Texas MD Anderson Cancer Center
Journal: Link
Date: 6/2012

This phase 2 study involved 13 patients with low-grade serous carcinoma (LGSC) of the ovary, peritoneum, or fallopian tube who had previously been treated with platinum- and taxane-based chemotherapy. The median patient age was 52 years.

Patients were treated with the biologic therapy agent imatinib mesylate, which is a tyrosine kinase inhibitor that interferes with cancer cell growth.

The most severe toxicities were of grade 3 and included granulocytopenia and rash. Grade 1-2 fatigue (66% of patients), nausea/vomiting (66%), and diarrhea (41%) were also reported.

The median overall survival was 14.9 months.

Correspondence: Dr. David M. Gershenson; email:

E-mail to a Friend Email Physician More Information